421
Participants
Start Date
June 11, 2021
Primary Completion Date
December 8, 2023
Study Completion Date
October 11, 2024
BD0801
Subjects receive BD0801 , intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
Paclitaxel
Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, d22, q4w, Dosage form: injectable, Strength: 80 mg/m2
Placebo
Subjects receive Placebo, intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
Topotecan
Subjects receive Topotecan, intravenously, d1, d8, d15, q4w, Dosage form: injectable, Strength: 4mg/m2
doxorubicin liposome
Subjects receive doxorubicin liposome, intravenously, d1, , q4w, Dosage form: injectable, Strength: 40mg/m2
The First Affiliated Hospital of Bengbu Medical University, Bengbu
The First Affiliated Hospital of USTC West District,Anhui Provincial Cancer Hospital, Hefei
The Second Hospital of Anhui Medical University, Hefei
Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Peking University First Hospital, Beijing
Chongqing Cancer Hospital, Chongqing
Fujian Provincial Cancer Hospital, Fuzhou
Sun Yat-sen University Cancer Center, Guangzhou
Zhujiang Hospital of Southern Medical University, Guangzhou
Cancer Hospital of Shantou University Medical College, Shantou
Cancer Hospital Chinese Academy Of Medical Sciences, Shenzhen Center, Shenzhen
Guangxi Medical University Cancer Hospital&Guangxi Cancer Institute, Guangxi Cancer Hospital&Medical University School&Cancer Center, Nanning
Guizhou Provincial People's Hospital, Guiyang
Hainan General Hospital, Haikou
The Fourth Hospital of Hebei Medical University, Shijiazhuang
The Second Hospital of Hebei Medical University, Shijiazhuang
Harbin Medical University Cancer Hospital, Harbin
The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
The Second Affiliated Hospital of Zhengzhou University, Zhengzhou
Hubei Cancer Hospital, Wuhan
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Hunan Cancer Hospital, Changsha
The Second Xiangya Hospital of Central South University, Changsha
The First Affiliated Hospital of University of South China, Hengyang
Jiangsu Cancer Hospital, Nanjing
Nanjing Women and Children's Healthcare Hospital, Women's Hospital of Nanjing Medical University, Nanjing
Nantong Cancer Hospital, Nantong
Xuzhou Central Hospital(Southeast University Affiliated Hospital), Xuzhou
Jiangxi Maternal and Child Health Hospital, Nanchang
Jilin Cancer Hospital, Changchun
The First Hospital of Jilin University, Changchun
The Second Norman Bethune Hospital of Jilin University, Changchun
The Second Hospital of Dalian Medical University, Dalian
Fukuang General Hospital of Liaoning Health Industry Group, Fushun
Liaoning Cancer Hospital & Institute, Shenyang
Shengjing Hospital of China Medical University, Shenyang
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Qilu Hospital of Shandong University, Jinan
Shandong Cancer Hospital & Institute, Jinan
Affiliated Hospital of Jining Medical University, Jining
Linyi Cancer Hospital, Linyi
Yantai Yuhuangding Hospital, Yantai
Obstetrics & Gynecology Hospital of Fudan University, Shanghai
Second Hospital of Shanxi Medical University, Taiyuan
Mianyang Central Hospital, Mianyang
Affiliated Hospital of North Sichuan Medical College, Nanchong
Tianjin Center Hospital of Gynecology Obstetrics, Tianjin
Tianjin Medical University Cancer Institute & Hospital, Tianjin
Hangzhou Cancer Hospital, Hangzhou
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
Zhejiang Provincial People's Hospital, Hangzhou
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
Lead Sponsor
Shanghai Xianxiang Medical Technology Co., Ltd.
INDUSTRY
Jiangsu Simcere Pharmaceutical Co., Ltd.
INDUSTRY